BioElectronics Corporation

Makers of ActiPatch™ a drug-free,
anti-inflammatory patch that resolves swelling

BioElectronics has taken proven medical technologies and made them available to more people in new convenient, cost-effective, anti-inflammatory patches.  By applying advanced microelectronic technology, BioElectronics has dramatically reduced the size and the cost of some well-established medical treatments.

BioElectronics is the developer and marketer of  ActiPatch™ medical devices which deliver pulsed electromagnetic frequency (PEMF) therapies to accelerate healing of soft tissue injuries. A reduction of pain and swelling allows patients to return to normal activities much sooner. This patented technology is based on clinically proven, widely accepted PEMF therapy.

The Company's ActiPatch is a drug-free, painless, pulsed energy patch. The ActiPatch has FDA clearance for the treatment of edema following blepharoplasty.

We deliver a solution that:

• Is drug-free
• Reduces swelling and inflammation
• Lasts 10 to 30 days, depending on model
• Is comfortable
• Provides continuous treatment
• Is easy to use
• Is safe
• Is affordable
• Provides localized, non-systemic treatment
• Is lightweight

• Not A Magnet - ActiPatch delivers a pulsed electromagnetic field.
• Not Heat Therapy - ActiPatch is heat free, not a diathermy unit.
• Not A TENS Unit - Unlike TENS, PEMF does not deliver an electrical current through the body to block pain.
• Not A Pharmaceutical - ActiPatch in not ingested or injected and is not systemic.
• Not An Office Based Therapy - ActiPatch can be worn in the comfort of the patient's home.
• Not A Bone Growth Stimulator - ActiPatch delivers a low power pulse and is not designed to heal hard tissue (bone).

• FDA market clearance for the treatment of edema
• International Standards Organization (ISO) and CE (Conformité Européenne, French for European conformity) Certifications
• Health Canada Market clearance for the relief of musculoskeletal pain
• Strong intellectual property
• Active sales and marketing support.

The clinical effectiveness of the product has been well established. Testing performed at the Bioelectromagnetics Research Laboratory at the State University of New York has shown that ActiPatch Therapy provides an adequate dosage of electromagnetic energy for the treatment of soft tissue, and that its power at the skin level is equivalent to that of traditional high-power devices. The power level is six to nine orders of magnitude higher than that which is required to show a biological effect. It also demonstrated that the cumulative effect of continuous delivery provides greater therapeutic benefit than sporadic treatments. More information on the testing and clinical effectiveness of our product can be found at the following web site: http://femu.de/.

Clinical Trials

In 2006, the Company and the Lahey Clinic jointly announced a three-year program to study the effects of ActiPatch Therapy on a variety of soft tissue injuries and related medical conditions. The internationally renowned Lahey Clinic of Boston, whose faculty is affiliated with the Medical Schools of Harvard and Tufts, has committed to initiating a number of double-blind clinical studies on ActiPatch Therapy in the areas of plastic surgery, orthopedics and chronic wound care. Results from these clinical trials will be submitted to the United States Food and Drug Administration (the FDA) for expanded indications for the use of ActiPatch Therapy.

The company also commenced a series of double-blind clinical trials to be conducted in conjunction with leading schools of podiatry and selected clinics to document the effects of ActiPatch on treating plantar fasciitis [heel pain]. The studies in started in March 2006. The Principal Investigator for the study is Dr. William Van der Reis, a Board Certified Orthopedic Surgeon and sports medicine specialist. The study protocol was approved by the Investigational Review Board, Coast IRB, of San Clemente, CA.

Drug-free therapy in a patch.

Click here to see ActiPatch™ brochure

Real World Experiences with ActiPatch Therapy are documented in Dr. Brian Kinney's article in Plastic Surgery Products.  Read it here.

BioMechanics Magazine: In the September, 2006 issue there is a feature article on ActiPatch Therapy by Michael Metzger, DPM, MBA. "Miniaturization Prompts Reconsideration of PEMF Therapy"  Read it here.

DVD on ActiPatch Therapy narrated by Lawrence Michaelis, MD, MS, and William Van der Reis, MD. You will need Quicktime to view this presentation. To download Quicktime Player click here. View the movie (Please be patient with download time)

On November 15, 2006 our CEO, Andrew Whelan was interviewed by the Green Baron. To listen to the webcast click on the link below. Listen to the Interview